

**Toxicological Analysis of Tacrines and Verapamils to the  
Yellow Fever Mosquito, *Aedes aegypti***

Ngoc N. Pham

Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in  
partial fulfillment of the requirements for the degree of

Master of Science in Life Science  
Entomology

Troy D. Anderson  
Paul R. Carlier  
Jianyong Li  
Sally L. Paulson  
Carlyle C. Brewster

February 18, 2016  
Blacksburg, Virginia

Keywords: mosquito, tacrines, verapamil, acetylcholinesterase ATPase activity, ABC transporter

Copyright 2016, Ngoc Pham

Toxicological Analysis of Tacrines and Verapamil on the  
Yellow Fever Mosquito, *Aedes aegypti*

Ngoc N. Pham

ABSTRACT

Mosquitoes affect human health worldwide as a result of their ability to vector multiple diseases. Mosquitocide resistance is a serious public health challenge that warrants the development of improved chemical control strategies for mosquitoes. Previous studies demonstrate the mosquito blood-brain barrier (BBB) to interfere with the target-site delivery and action of anticholinesterase chemistries. The ATP-binding cassette (ABC) transporters are efflux proteins that assist in maintaining the BBB interface and serve as a first line of defense to mosquitocide exposures. To date, there are three subfamilies (ABC -B, -C, -G) of ABC transporters; however, knowledge of these chemistries interacting with mosquito ABC transporter(s) is limited. Here, I report that tacrine and *bis(7)*-tacrine are relative non-toxic anticholinesterases at solubility limits; however, the addition of verapamil enhances toxicity of both tacrine and *bis(7)*-tacrine to mosquitoes. Verapamil significantly increases the mortality of mosquitoes exposed to tacrine and *bis(7)*-tacrine compared to the tacrine- and *bis(7)*- tacrine-only treatments. Tacrine and *bis(7)*-tacrine reduce acetylcholinesterase activity in mosquito head preparations compared to the untreated mosquitoes; however, the addition of verapamil significantly increases the anticholinesterase activity of tacrine and *bis(7)*-tacrine compared to the tacrine-and *bis(7)*-tacrine-only treatments. Tacrine and *bis(7)*-tacrine increase ATPase activity in *Aedes aegypti* at lower concentrations compared to that of verapamil (Fig. 3). The

differential increase in ATPase activity suggests that tacrine and *bis(7)*-tacrine are more suitable substrates for ABC transporter(s) compared to verapamil and, thus, provides putative evidence that ABC transporter(s) is a pharmacological obstacle to the delivery of these anticholinesterases to their intended target site.

Toxicological Analysis of Tacrines and Verapamil on the  
Yellow Fever Mosquito, *Aedes aegypti*

Ngoc N. Pham

GENERAL AUDIENCE ABSTRACT

Mosquitoes affect human health worldwide as a result of their ability to vector multiple diseases. Widespread resistance limits the use of current mosquitocide chemistries to reduce the risk of mosquito-vectored diseases. Thus, mosquitocide resistance is a serious public health challenge that warrants the development of improved mosquitocide control strategies for these disease vectors. Previous studies demonstrate the mosquito blood-brain barrier (BBB) to interfere with the target-site delivery and action of anticholinesterase chemistries. The ATP-binding cassette (ABC) transporters are efflux proteins that assist in maintaining the BBB interface of mosquitoes and serves as a first line of defense to mosquitocide exposures. To date, there are three subfamilies (ABC –B, -C, -G) of ABC transporters that are implicated to confer multi-specific mosquitocide resistance in mosquitoes; however, knowledge of these chemistries interacting with mosquito ABC transporter(s) is limited. My results suggest that ATP-binding cassette transporter positioned within the blood brain barrier could be involved in the BBB penetration issue of target site delivery of tacrines to the central nervous system. Additionally, I show that ABC transporters causes an increase in toxicity in tacrine based compounds in mosquitoes when exposed to a combination of a ABC transporter inhibitor such as verapamil. Overall, this research indicates that ABC transporters are potential pharmacological targets that may be used to enhance the effectiveness of insecticides. However, further research is needed to confirm

these targets before it could be used in commercial use. In a broader sense, this research further implicates ABC transporters as a possible resistance mechanism.

## **Acknowledgements**

I would like to acknowledge the professors, staff, and students that helped to make this project happen. My sincere thanks to Dr. Troy Anderson, my committee chair, for his invaluable advice and direction. I would like to thank him for helping me grow into the person I am today with his consistent advice on everything. I am thankful to Dr. Bloomquist for his leading me into science and his consistent care for me over the year. Dr. Carlyle Brewster, Dr. Sally Paulson, Dr. Paul Carlier, and Dr. Jianyong Li for constantly answering all my silly questions and providing enormous support over the years. I appreciate all of the office staff in the Entomology Department. In addition, I am thankful to my lab mates Nicholas Larson, Jen Williams, Kurt Langberg, Sara Scates, Phi Vu, Scott O'Neal, Alison Reeves, Ian Sandum, and Bryant Gabriel. Thanks to Jake Bova for being there for support. A special thanks to all the entomology graduate students for keeping me sane. I am so very grateful to my friends and family for constantly providing me support. Especially big thanks for my amazing mom for listening to my constant rambling. A special thanks to Li Lin for always being there for me and keeping me on track. Thank you all for keeping me grounded and for your kindness and love.

## Table of Contents

<b>Abstract</b> .....	
<b>General Audience Abstract</b> .....	
<b>Acknowledgements</b> .....	i
<b>Table of Contents</b> .....	ii
<b>List of Figures and Tables</b> .....	iv
<b>Chapter 1: Introduction</b> .....	1
1.1 Introduction .....	8
<b>Chapter 2: Literature Review</b> .....	11
2.1 Expansion of Mosquito Vected-Diseases .....	11
2.2 Mosquito Borne Diseases .....	12
2.3 Insecticide Resistance.....	12
2.3.1 Chemical Control Strategies.....	12
2.3.2 Metabolic Detoxification.....	13
2.3.3 Mosquito ABC Transporters .....	17
<b>Chapter 3: Increased Toxicity of Tacrine and <i>Bis(7)</i>-Tacrine in Combination with Verapamil to Adult Mosquitoes</b> .....	18
3.1 Introduction .....	18
3.2 Material and Methods.....	20
3.2.1 Chemicals .....	20
3.2.2 Mosquito Colony Maintenance .....	21
3.2.3 Individual Acute Toxicity Bioassays.....	22
3.2.4 Binary Toxicity Bioassays.....	22
3.2.5 Statistical Analysis .....	23
3.3 Results .....	24
3.3.1 Individual Acute Toxicity Bioassays.....	24
3.3.2 Table and Figures .....	25
3.4 Discussion .....	27
<b>Chapter 4</b> .....	30
4.1 Introduction .....	30

4.2 Material and Methods.....	33
4.2.1 Chemicals .....	33
4.2.2 In Vivo Inhibition of Acetylcholinesterase Activity .....	34
4.2.3 In Vitro Activity of ATPase synthases .....	35
4.2.4 Measurement of Total Protein Content .....	35
4.2.5 Statistical Analysis .....	36
4.3 Results .....	36
4.3.1 In Vivo Inhibition of Acetylcholinesterase Activity .....	36
4.3.2 In Vitro Analysis of ABC Transporter ATPase Activity .....	37
4.3.2 Table and Figures .....	39
4.4 Discussion.....	41
<b>Chapter 5: Summary .....</b>	<b>43</b>
<b>References .....</b>	<b>46</b>

## List of Figures and Tables

Table 1. Toxicity of tacrine, <i>bis(7)</i> -tacrine, and verapamil, alone and in combination, to adult mosquitoes, <i>Ae. aegypti</i> .....	20
Figure 1. Percent mortality of adult mosquitoes, <i>Ae. aegypti</i> , exposed to tacrine (THA) or <i>bis(7)</i> -tacrine (7-THA) alone and in combination with verapamil (VER).....	21
Figure 2. Residual acetylcholinesterase (AChE) activity of adult mosquitoes, <i>Ae. aegypti</i> , exposed to tacrine or <i>bis(7)</i> -tacrine (AChE inhibitors) alone or in combination with verapamil (ABC transporter inhibitor).....	32
Figure 3. Adult mosquito, <i>Ae. aegypti</i> , and human ATPase activity treated with ABC transporter substrates.....	33

## CHAPTER 1

### 1.1 Introduction

The yellow fever mosquito, *Aedes aegypti*, affects millions of people worldwide. Dengue, chikungunya, and yellow fever are life-threatening diseases vectored by this mosquito species. There are few effective strategies to control malarial mosquitoes, including insecticide-treated nets (ITNs) and indoor residual spraying (IRS) (Okumu et al. 2011). However, there are numerous biochemical and physiological adaptations that allow *Aedes* mosquitoes to survive lethal exposures to current-use insecticides, including mechanisms of decreased insecticide response (i.e., target-site resistance) or mechanisms of decreased insecticide exposure (i.e., metabolic resistance) (Vontas et al. 2012).

The serine hydrolase acetylcholinesterase (AChE) of *Ae. aegypti* rapidly hydrolyzes the neurotransmitter acetylcholine (ACh), thereby terminating cholinergic nerve transmission. AChE is a proven target site for high efficacy insecticides (e.g., carbamate and organophosphate insecticides); however, widespread insecticide resistance limits their use for chemically based mosquito control strategies. For example, Wong et al. (2012) confirmed a single amino acid mutation of AChE (i.e., G119S) that confers target-site resistance in mosquito. In addition, these anticholinesterase insecticide-resistant mosquitoes are reported to have increased cytochrome P450 monooxygenase, esterase, and glutathione *S*-transferase metabolic activities compared to anticholinesterase insecticide-susceptible mosquitoes (Mutunga et al. 2015). Previously, a pharmacological approach with novel *bis*(n)-tacrine anticholinesterases was conducted to profile the AChE of mosquitoes (Anderson et al. 2009). The bivalent *bis*(n)-tacrine (n = 2 - 12

methylene linkers) showed a tether-length dependence towards AChE of multiple mosquito species, with greater maximal potency for *bis(7)*-tacrine compared to tacrine or other *bis(n)*-tacrine anticholinesterases (Anderson et al. 2009). While this information has implications for the identification of unique AChE target sites for the development of anticholinesterase insecticides for mosquitoes, neither tacrine nor *bis(7)*-tacrine was lethal to the mosquitoes. Mutunga et al. (2013) report that the lack of observed mosquito toxicity to the *bis(n)*-tacrine might be due to the inability of the chemical to penetrate the blood-brain barrier and, in turn, impedes the target-site delivery of these anticholinesterases.

The blood-brain barrier of insects is composed of ATP-binding cassette (ABC) transporters that prevent the uptake and elimination of insecticides, thereby inhibiting the ability to target the central nervous system (Porretta et al. 2008). These ABC transporters serve as the first line of cellular defense for insects exposed to insecticides. ABC transporters that confer a multi-drug resistance (MDR) phenotype are of particular interest and have often been associated with insecticide resistance (Buss et al. 2002, Porretta et al. 2008). In *Ae. aegypti*, there are currently 44 ABC transporter proteins described within at least three subfamilies that confer a multi-drug resistance phenotype, including (i) 5 ABC sub-family B transporters for the efflux of hydrophobic insecticides, (ii) 14 ABC sub-family C family transporters for the export of insecticide conjugates (e.g., glutathione conjugates), and (iii) 12 ABC sub-family G family transporters with broad substrate specificity for the efflux of insecticides (Roth et al. 2003). To date, ABC transporter-mediated insecticide resistance has been reported for a small number of insect pests (Buss et al. 2002, Porretta et al. 2008); however, the interaction of ABC transporters towards tacrine-based compounds that inhibit mosquito AChE remains unknown.

The overall hypothesis behind this proposed research is that ABC transporters impede the ability of tacrine-based compounds to inhibit AChE and, thus, reduce the toxicity of these anticholinesterases to *Ae. aegypti*. Based on the above observations, the experimental focus was to examine the possible link between ABC transporter activity and AChE inhibition of these mosquitoes. The objectives of this research project were to examine (i) the individual acute toxicity, (ii) the binary acute toxicity, (iii) the AChE inhibition and (iv) the ATPase activity of *Ae. aegypti* exposed to verapamil (ABC transporter inhibitor) and tacrines (AChE inhibitors).

## CHAPTER 2

### LITERATURE REVIEW

#### **2.1 Expansion of Mosquito Vectored-Diseases**

The geographic distribution of numerous arthropod vectors and diseases has expanded worldwide causing a dramatic increase in cases and epidemics (Gubler et al. 2002). Previous public health policy and eradication control programs have reduced cases of vector-borne diseases in certain areas. Chemical control programs started in the 1900s after mosquitoes were discovered to transmit malaria parasites, making eradication an important concentration. However, the reductions of prevention efforts, increase of insecticide resistance, and change in human expansion have caused a resurgence or emergence of diseases. This change has allowed mosquitoes to overcome geographic barriers and adapt physiologically to diverse environmental conditions (Tatem et al. 2006), leading to emergence of vector-borne diseases. Recent biological invasions have included both insect disease vectors and the expansion or reemergence of vector-borne diseases. The change in human global air travel and application of chemical control programs reduced populations of insect-vectored diseases. Direct exposure to humans or animals infected with diseases increased the virus reproductive numbers and transmission rate from insects (Gubler et al. 2002). Due to their host preference variability, variation in mosquito behavior, vector biodiversity, and ecological adaptations, mosquitoes are the most important vector-borne arthropods that affect humans (Ferguson et al. 2010). The main impact on vector-borne disease viability comes from insecticide resistance resulting in an increase of mosquito populations. Mosquitoes affect millions of people worldwide as a result of their ability to vector multiple infectious diseases such as dengue, yellow fever, and chickungunya (Hemingway et al. 2006). Dengue is consider the most important arthropod borne disease in the 20<sup>th</sup> century (CDC

2010). With no effective treatment or commercial vaccine available, control strategies are focused on its primary mosquito vector, *Aedes aegypti* (WHO 2009, Bhatt et al. 2013).

## **2.2 Mosquito Borne Diseases**

Yellow fever, dengue, chikungunya, and zika fever are life-threatening diseases vectored by the *Aedes* mosquitoes, principally *Aedes aegypti*. This mosquito is widely distributed around the world with numbers increasing annually. Dengue is estimated to infect 390 million people yearly or 40% of the world's populations are at risk for endemic transmission (Bhatt et al 2013). There is currently no effective vaccine or drug treatment, therefore, prevention is focused on supportive care of symptoms to treat dengue infections (WHO 2009). Dengue, an arbovirus in the family Flaviviridae is transmitted by *Ae. aegypti*. There are four serotypes of the dengue virus, Den 1,2,3,4. *Ae. aegypti* mosquitoes thrive in both urban and rural area. Current control methods are focused on chemical, biological, and vector control of the *Aedes* mosquitoes. However, a surge of transmission rates and an increase in outbreaks of infection numbers have resulted from misuse of insecticides, financial burdens, and low prevention methods in developing and underdeveloped countries.

## **2.3 Insecticide Resistance**

### *2.3.1 Chemical Control Strategies*

The mosquito central nervous system is a proven target site for high efficacy insecticides, including carbamate-, organophosphate-, and pyrethroid-class chemistries. These insecticides work to kill mosquitoes by targeting acetylcholinesterase (AChE) and voltage-gated sodium channels (VGSC). Carbamate and organophosphate insecticides are AChE inhibitors that cause

acetylcholine to accumulate at the nerve synapse resulting in excessive excitation of cholinergic receptors leading to paralysis and death of the mosquito (Casida et al. 2004). Pyrethroids target the VGSC to extend the course of sodium current depolarization of the axon, thereby resulting in uncontrolled and persistent excitation of the neurons (Bloomquist 1999). There are few effective strategies to control *Ae. aegypti*, including insecticide-treated nets (ITNs) and indoor residual spraying (IRS) (Okumu et al. 2011). There are numerous biochemical and physiological adaptations that allow mosquitoes to survive lethal doses of current-use insecticides, including mechanisms of decreased insecticide response (i.e., target-site resistance) or mechanisms of decreased insecticide exposure (i.e., metabolic resistance) (Vontas et al. 2012).

### 2.3.2 *Metabolic Detoxification*

The biochemistry of insecticide resistance is important to understand the detoxifying enzymes when attempting to mitigate resistance through the manipulation of components or compound chemistries. Glutathione S-transferases (GST), esterases, and cytochrome P450 monooxygenases are three major enzyme groups responsible for metabolic resistance to organophosphates, organochlorines, carbamates, and pyrethroids (Hemingway et al. 2002). These enzymes recognize and modify compounds to reduce biological activity and decrease lipophilicity (Phase I) and conjugate metabolites to endogenous molecules for excretion (Phase II) (Casida et al. 2004). The effectiveness of these insecticides has diminished as a result of the increasing incidence of either target-site or metabolic detoxification resistance.

Biochemical characterization of metabolic resistance arising from cytochrome P450 monooxygenases, carboxylesterases, and glutathione S-transferases are groups of enzymes found

in the majority of animals, including insects to be responsible for metabolic resistance (Hemingway and Ranson, 2000). The cytochrome P450 monooxygenases are dimeric multi-functional enzymes that are involved in the detoxification of a wide range of insecticides (Prapanthadara et al. 1996). These enzymes can increase resistance by activating or deactivating the main toxic metabolite of the insecticide into a more hydrophilic and normally less toxic substrate that does not react the target site (Hemingway 2000). Resistance to insecticides are associated with pyrethroid resistance due to over expression of cytochrome P450 monooxygenases leading to increased metabolic breakdown of insecticides for detoxification purposes (Scott et al. 2015). The cytochrome P450 monooxygenases have been implicated in the development of insecticide resistance in *Aedes* mosquitoes (Ranson 2000). Cytochrome P450 monooxygenases are a group of enzymes found in most organisms, including insects. These enzymes play a role in the metabolism of insecticides and are involved in endogenous metabolism of compounds. The catalytic action of cytochrome P450 monooxygenases enzymes is through the oxygenation of an insecticide via uptake of electrons from NADPH (Hemingway et al. 2000). Insecticide resistance has been associated with the activation of cytochrome P450 monooxygenases leading to increased expressions of ABC transporter proteins to excrete addition insecticides (Bariami et al. 2012; Dauchy et al. 2008).

Likewise, the glutathione *S*-transferases (GST) are dimeric multi-functional enzymes that are involved in the detoxification of a wide range of insecticides (Prapanthara et al., 1996; Ranson et al. 2001). These enzymes can increase resistance by conjugating glutathione (GSH) with the alkyl group of the insecticide or with the leaving group of the main toxic metabolite (Hemingway 2000). GSTs play a role in insecticide resistance due to elevated levels of

metabolic activity increase reductive dehydrochlorination using reduced glutathione, to produce water soluble metabolites that are readily excreted in many insect species, thereby preventing the insecticide to reach the target site (Yu et al. 1996; Enayati et al. 2005).

A wide range of medically important insect species, including mosquitoes, have been found to exhibit general esterase-based resistance to multiple insecticide groups such as organophosphate, carbamate, and pyrethroid insecticides (Hemingway et al. 2006, Hemingway et al. 2002). General esterases are a group of enzymes that work by hydrolyzing carboxylic esters in insecticides (Hemingway et al. 2000). Resistances to insecticides have been associated with esterases due to its ability to rapid sequestration rather than metabolization of the insecticide. The increase amplification of general esterase genes has been found in bed bugs, midges, and mosquitoes with enhanced hydrolysis and sequestration of organophosphates, carbamates, and pyrethroids (Adelman et al. 2011; McCarroll et al. 2000; Jin-Clark et al. 2008; Yu et al 2008).

Insecticide resistance due to reduced cuticular penetration is a common mechanism of resistance in insect populations. Reduced cuticular penetration provides slight resistance to insecticide exposures; however, in combination with other insecticide resistance mechanisms, it confers considerable resistance to insecticide exposures (Yu 2008; Wood et al. 2010). The reduced cuticular penetration of insecticides is suggested to be due to the affinity of the binding protein, lipid composition to prevent the penetration of insecticide, a degrading enzyme, or an impermeable layer of the cuticle (Yu et al. 2008). Structure activity relationships have suggested that the more polar molecules are more capable of penetrating the cuticle but are quickly dissociated from the intracellular environment, reducing toxicity (Dauchy et al. 2008; Vision and

Law 1971). These mechanisms have been implicated for insecticide resistance in tobacco budworm, mosquitoes, bollworm, cabbage looper and several other insect species (Anderson et al. 2009; Vinson and Law 1971; Ahmad et al. 2006; Tak et al. 2015).

Acetylcholinesterase (AChE) is a proven target site for high efficacy insecticides, including carbamates and organophosphates; however, widespread insecticide resistance limits their use for chemically based mosquito control strategies. For example, Wong et al. (2012) recently confirmed a single amino acid mutation of AChE (i.e., G119S) that confers target-site resistance in mosquitoes. Previously, a pharmacological approach with novel *bis*(n)-tacrine anticholinesterases was conducted to profile the AChE of mosquitoes (Anderson et al. 2009). The bivalent *bis*(n)-tacrine (n = 2 – 12 methylene linkers) showed a tether length dependence towards mosquito AChE, and other mosquito species, with greater maximal potency for *bis*(7)-tacrine compared to tacrine or other *bis*(n)-tacrine anticholinesterases (Anderson et al. 2009). While this information has implications for the identification of unique AChE target sites for the development of AChE-inhibiting insecticides for mosquitoes, neither tacrine nor *bis*(7)-tacrine was lethal to the mosquitoes. Mutunga et al. (2013) findings suggest the blood-brain barrier can prevent the penetration of the *bis*(n)-tacrine, thereby, impeding the target-site delivery of these anticholinesterases to the central nervous system, consistent with the lack of observed toxicity.

### 2.3.3 Mosquito ABC Transporters

The blood-brain barrier of insects is composed of ATP-binding cassette (ABC) transporters that prevent the uptake and elimination of insecticides, thereby inhibiting their ability to target the central nervous system (Porretta et al. 2008). The ABC transporters may serve as the first line of

cellular defense for insects exposed to insecticides. The ABC transporters that confer the multi-drug resistance (MDR) phenotype, or P-glycoproteins (P-gps), are of particular interest and have often been associated with insecticide resistance (Buss et al. 2002, Poretta et al. 2008). ABC transporters have been typically associated in the gut, malpighian tubules, and the cuticular epithelium of insects (Broehan et al 2013; Labbe et al 2010; Mayer et al. 2009; Leader and O'Donnell 2005). To date, ABC transporter(s)-mediated insecticide resistance has been reported for a small number of medically important insect pests (Buss et al. 2002, Porretta et al. 2008). Recent reports have revealed ABC transporter(s) modification of insecticide toxicity in *Ae. caspius* and *Culex pipens* (Buss et al. 2002, Porretta et al. 2008). Insecticide resistance has been shown in species with an over-expression of ABC transporters (Simmons et al. 2013; Figueira et al 2013). ABC transporters function by hydrolyzing ATP and moving chemicals and other substrates across cellular membranes (Lopez et al 2014). For example, Figueria et al. (2013) reported that insecticides are able to increase the toxicity of tempos by 24% when in combination with the ABC transporter inhibitor verapamil. However, the interaction of ABC transporters towards anticholinesterase insecticides for mosquito control remains unclear.

## CHAPTER 3

### INCREASED TOXICITY OF TACRINE AND *BIS(7)*-TACRINE IN COMBINATION WITH VERAPAMIL TO ADULT MOSQUITOES

#### 3.1 Introduction

The *Aedes* mosquitoes affect millions of people worldwide as a result of their ability to transmit dengue fever, chikungunya, and yellow fever, thus posing a major long term public health problem for numerous countries (Vontas et al. 2012). Dengue fever, yellow fever, and dengue-dengue hemorrhagic fever are considered the most important mosquito-borne vectored diseases that affect humans (CDC 2014). Dengue affects nearly one million people annually and an estimated 3 billion people or 40% of the world's population, are at risk for endemic transmission (Bhatt et al 2013). The mosquito nervous system is a proven target site for high efficacy chemistries, including the carbamate-, organophosphates-, and pyrethroid-class insecticides (Anderson et al. 2009, Hartsel et al. 2012, Wong et al. 2012). However, both target-site and metabolic resistance limits the use of these insecticidal chemistries to reduce the risk of *Aedes*-borne diseases. Thus, new and improved chemical control strategies are required for vector mosquitoes.

Acetylcholinesterase is a target site for carbamates and organophosphate insecticides; however, widespread insecticide resistance limits their use for chemically based mosquito control strategies. For example, Wong et al. (2012) recently confirmed a single amino acid mutation of AChE (i.e., G119S) that confers target site resistance in mosquitoes. Previously, a

23 pharmacological approach with novel *bis(n)*-tacrine anticholinesterases was conducted to profile  
24 the AChE of mosquitoes (Anderson et al. 2009). The bivalent *bis(n)*-tacrine ( $n = 2 - 12$   
25 methylene linkers) showed a tether length dependence towards mosquito AChE, and other  
26 mosquito species, with greater maximal potency for *bis(7)*-tacrine compared to tacrine or other  
27 *bis(n)*-tacrine anticholinesterases (Anderson et al. 2009). While this information has  
28 implications for identification of unique AChE target sites for the development of  
29 anticholinesterase insecticides for mosquitoes, neither tacrine nor *bis(7)*-tacrine was found to be  
30 lethal to the mosquitoes. Mutunga et al. (2013) report that the lack of observed mosquito toxicity  
31 to the tacrine is due to their inability to penetrate the blood-brain barrier of insects, thereby  
32 impeding the target site action of these anticholinesterases.

33  
34 The blood-brain barrier of insects is composed of ATP binding cassette (ABC) transporters that  
35 prevent the uptake and elimination of insecticides, thereby inhibiting their ability to target the  
36 central nervous system (Porretta et al. 2008). These ABC proteins are present in all kingdoms of  
37 life and are one of the largest transporter families (Dermauw and Van Leeuwen 2013). The  
38 majority of these ABC proteins hydrolyze ATP to transport substrates or non-substrates across  
39 lipid membranes as primary active transporters (Dermauw and Van Leeuwen 2013). Thus, ABC  
40 proteins may serve as the first line of cellular defense for insects exposed to insecticides. The  
41 ABC transporters that confer the multi-drug resistance (MDR) phenotype, also known as P-  
42 glycoprotein (P-gp), are of particular interest and have often been associated with insecticide  
43 resistance (Buss et al. 2002, Porretta et al. 2008). To date, ABC transporters-mediated insecticide  
44 resistance has been reported for numerous medically important insect pests (Buss et al. 2002,  
45 Porretta et al. 2008). Recent reports have revealed ABC transporters modification of insecticide

46 toxicity in *Aedes caspius*, *Culex pipens*, and *Ae. aegypti* (Buss et al. 2002, Porretta et al. 2008,  
47 Figueria-Mansur et al. 2013). The increased expression of ABC transporter(s) has been reported  
48 in insecticide-resistant insects (Simmons et al. 2012). In addition, ABC transporters have been  
49 shown to have multiple primary active drug-binding transport sites on the transmembrane  
50 domain (Labbe et al. 2013; Zhang et al 2003; Dermauw and Van Leeuwen 2013). Photonaffinity  
51 labeling studies have revealed up to seven different drug binding sites associated with ABC  
52 transporters which contain multiple binding sites for different substrates and non-substrates  
53 (Zhang et al. 2003; Safa 2004). Substrates and modulators can bind to the secondary binding  
54 sites that cooperate with drug binding or transport sites (Lespine et al. 2012). However, the  
55 interaction of mosquito ABC transporters with anticholinesterase compounds remains unclear.

56

57 This study examined the acute toxicity of tacrine and *bis(7)*-tacrine (AChE inhibitors) alone and  
58 in combination with verapamil (ABC transporter inhibitor) to the yellow fever mosquito, *Ae.*  
59 *aegypti*. Herein, I report the: 1) individual acute toxicity of tacrine, *bis(7)*-tacrine, and verapamil  
60 to *Ae. aegypti*, and 2) the binary acute toxicity of tacrine, *bis(7)*-tacrine, and verapamil to *Ae.*  
61 *aegypti*.

62

## 63 3.2 Material and Methods

### 64 3.2.1 Chemicals

65 *Bis(7)*-tacrine, dimethyl sulfoxide (DMSO), ethanol, magnesium chloride (MgCl<sub>2</sub>), and tacrine  
66 were purchased from Fisher Scientific (Pittsburg, PA). Acetylthiocholine iodide (ATCh),  
67 adenosine 5'triphosphate disodium salt (ATP-Na), 5,5'-dithio-bis (2-nitrobenzoic acid) (DTNB),  
68 ethylene glycol-*bis*(2-aminoethylether)-N,N,N'N'-tetraacetic acid(EGTA), *n*-phenylthiourea,

69 protease inhibitor cocktail, potassium nitrate (KNO<sub>3</sub>), phenylmethylsulfonyl fluoride (PMSF),  
70 sodium azide, sodium dodecyl sulphate (SDS), thapsigargin, trizma base (Tris hydrochloride,  
71 Tris-HCl), and Triton X-100 were purchased from Sigma-Aldrich (St. Louis, MO). Ouabain was  
72 purchased from Chem Service (West Chester, PA). Verapamil was purchased from INDOFINE  
73 Chemical Company, Inc. (Hillsborough, NJ).

74

### 75 **3.2.2 Mosquito Colony Maintenance**

76 A laboratory colony of *Aedes aegypti* (Liverpool strain) initially obtained from the Malaria  
77 Research and Reference Reagent Resource Center (MR4) (Manassas, VA), has been cultured in  
78 the Insect Toxicology and Pharmacology Laboratory at Virginia Tech (Blacksburg, VA) since  
79 2011. The mosquito colony was maintained according to the standard operating procedures  
80 described by Pridgeon et al. (2009) with slight modifications. The adult mosquitoes were held in  
81 a screened cage and provided 10% sucrose *ad libitum*. To encourage egg development in adult  
82 females, a membrane feeder containing defibrinated sheep blood (Colorado Serum Co., Denver,  
83 CO) was warmed to 37 °C and provided to the mosquitoes. The mosquito eggs were collected  
84 from the adult females and vacuum-hatched in a 1-L Erlenmeyer flask. The mosquito larvae  
85 were transferred to a plastic tray containing deionized water. A larval diet of flake fish food  
86 (Tetramin, Blacksburg, VA) was added to the plastic tray. The mosquito adults and larvae were  
87 reared in an environmental chamber at 28 °C and 75% relative humidity with a 16 h:8 h  
88 (light:dark) photoperiod.

89

### 90 **3.2.3 Individual Acute Toxicity Bioassays**

91 The acute toxicity bioassays were conducted for 24 h using 3-5 d old adult female mosquitoes  
92 exposed to six doses of tacrine, *bis-7-tacrine*, and verapamil to provide a range of 0-100%  
93 mortality. The appropriate dilutions of each compound were prepared in ethanol. Non-blood fed  
94 mosquitoes were collected with an aspirator and anesthetized on 4 °C chill plates. The  
95 compounds were delivered by adding 0.2 µl of compound solution to the dorsal thorax of 10  
96 mosquitoes per dose using a Hamilton PB600 repeating dispenser and a 700 series syringe  
97 (Reno, NV). The same procedure was used to treat mosquitoes with a corresponding dose of  
98 ethanol as a control treatment. The bioassays were repeated three times for each compound dose  
99 and control treatment. Treated adults were provided 10% sucrose solution and maintained in  
100 plastic cups in an environmental chamber at 28 °C and 75% relative humidity with a 16 h:8 h  
101 (light:dark) photoperiod. The endpoint for each bioassay was measured as a lethal dose (LD)  
102 according to World Health Organization guidelines (WHO 2006). Adult mosquito that was  
103 unable to right themselves were considered dead.

#### 104 *3.2.4 Binary Toxicity Bioassays*

105 The binary effect of tacrine, *bis(7)-tacrine* and verapamil was examined in 3-5 d old adult female  
106 mosquitoes treated with tacrine or *bis(7)-tacrine* at the solubility limit individually, 10  
107 µg/mosquito or 5 µg/mosquito, respectively and in combination with four treatments of  
108 verapamil. The different doses of verapamil were applied in 0.2 µl aliquots to the dorsal thorax  
109 of 10 mosquitoes per dose one hour prior to treatment with the solubility of tacrine or *bis(7)-*  
110 *tacrine* using a Hamilton PB600 repeating dispenser and a 700 series syringe (Reno, NV). The  
111 same procedure was used to treat mosquitoes with ethanol as a control treatment. The magnitude  
112 of altered toxicity was examined in female adult mosquitoes exposed to six doses, respectively,  
113 of tacrine and *bis-7-tacrine* individually and in combination with a single dose of verapamil.

114 Twenty-five mosquitoes were treated per replicate and repeated three times. Control treatments  
115 included an untreated, solvent (ethanol), and a verapamil control at 20 µg. The adult toxicity  
116 bioassays were conducted using the same procedures as those described above.

117

### 118 3.2.5 Statistical Analysis

119 A log-probit analysis using PoloPlus was used to estimate the LD<sub>50</sub> values for tacrine, *bis(7)-*  
120 tacrine, and verapamil for the individual and binary acute toxicity bioassays. The significant  
121 differences between the LD<sub>50</sub> for tacrine, *bis(7)-*tacrine, and verapamil individually and in  
122 combination with verapamil were based on the non-overlapping 95% confidence intervals  
123 estimated for each bioassay. The percentage of mosquitoes affected by the differences between  
124 each treatment were statistically compared to the control treatment using a one way analysis of  
125 variance (ANOVA) in combination with a Tukey's multiple comparison test.

126

## 127 3.3 Results

### 128 3.3.1 Individual Acute Toxicity Bioassays

129 Tacrine, *bis(7)-*tacrine, and verapamil were not acutely toxic, up to solubility limits in ethanol, to  
130 the mosquitoes under the tested bioassay conditions (Table 1). However, the acute toxicity of  
131 tacrine and *bis(7)-*tacrine was increased when applied in combination with verapamil, with 24-hr  
132 LD<sub>50</sub> values of 6.31 and 1.86 µg/mosquito, respectively (Table 1). Tacrine at 10 µg/mosquito in  
133 combination with verapamil at 0.1, 1, and 10 µg/mosquito significantly increased mosquito  
134 mortality 2.8-, 4.0-, and 5.2-fold, respectively, compared the tacrine-only treatment (Fig. 1).  
135 *Bis(7)-*tacrine at 5 µg/mosquito in combination with verapamil at 1 and 10 µg/mosquito

136 significantly increased mosquito mortality by 1.8- and 3.8-fold, respectively, compared to the  
137 *bis(7)*-tacrine-only treatment (Fig. 1).

138

### 139 **3.4 Discussion**

140 Due to the wide extent of insecticide application worldwide, insecticide resistance has resulted in  
141 significant emergence and re-emergence of diseases. Current chemical control strategies are  
142 concentrated on insecticide resistance such as target site and metabolic resistance. Previous  
143 studies have determined insecticide penetration issues due to the blood brain barrier (Mutunga et.  
144 al 2013). The blood-brain barrier of insects is composed of ATP binding cassette (ABC)  
145 transporters that prevent the uptake and elimination of insecticides, thereby inhibiting their  
146 ability to target the central nervous system (Porretta et al. 2008). This study aimed to provide  
147 evidence of ABC transporter modulation of insecticide transport in *Aedes aegypti* mosquitoes.  
148 We used tacrine and *bis(7)*-tacrine as our target site compound due to previous studies using  
149 these anticholinesterases to pharmacologically map the acetylcholinesterase active site gorge  
150 (Wong et al 2012). Verapamil was used to first determine the role of ABC transporter inhibitor  
151 in modulation of these insecticides in *Ae. aegypti*. This finding may provide further insights into  
152 ABC transporter interactions in mosquitoes and into drug resistance.

153

154 Here, I report that tacrine and *bis(7)*-tacrine up to 10 µg/mosquito and 5 µg/mosquito,  
155 respectively, did not show acute toxicity to mosquitoes, *Ae. aegypti*. However, we have  
156 determined that the toxicity of tacrine and *bis(7)*-tacrine was increased by 2- and 22-fold when in  
157 combination with verapamil (20 µg) as compared to anticholinesterase inhibitor-only treatments  
158 (Table 1). This suggest that the addition of the ABC transporter inhibitor verapamil enhances the

159 toxicity of tacrine and *bis(7)*-tacrine to *Ae. aegypti*. We determined that verapamil significantly  
160 increases the mortality of *Ae. aegypti* exposed to tacrine, when in combination with verapamil,  
161 by as much as *ca.* 77% compared to the tacrine-only treatment (Fig. 1). The mortality of  
162 mosquitoes exposed to *bis(7)*-tacrine in combination with verapamil was increased by *ca.* 60%  
163 compared to the *bis(7)*-tacrine-only treatment (Fig. 1).

164

165 This study indicates that the altered toxicity observed between verapamil and these  
166 anticholinesterases are associated with ABC transporter interference with transport of  
167 insecticides to their intended target site. This indicates that poor blood brain barrier penetration  
168 could be due to a possible resistance mechanism by mosquito ABC transporter to transport out  
169 substrates and non-substrates.

170

171 This study showed that tacrine and *bis(7)*-tacrine increase ATPase activity in *Ae. aegypti* at  
172 lower concentrations, compared to that of verapamil (Fig. 3). A previous study has demonstrated  
173 that suitable substrates such as verapamil are capable of facilitating reduced ATPase activity  
174 across the ABC transporters through blocking of active ATP sites (Taub et. al 2005). The  
175 differential increase in ATPase activity suggests that tacrine and *bis(7)*-tacrine are more suitable  
176 substrates for ABC transporters compared to verapamil and thus provide putative evidence that  
177 ABC transporters are a pharmacological obstacle to the delivery of these anticholinesterases to  
178 their intended target site. These data are in alignment with our previous studies that have  
179 confirmed the blood-brain barrier of *Drosophila melanogaster* to be a limiting factor in tacrine  
180 anticholinesterase toxicity (Mutunga et al. 2012).

181

182 In summary, this study reveals that verapamil significantly modifies the toxicity of  
183 anticholinesterase and that this altered toxicity may be the result of ABC transporters affecting  
184 the transport of compounds across the blood brain barrier. This study provides putative evidence  
185 for insecticide transport substrates (tacrine and *bis(7)*-tacrine) and inhibitory ligands (verapamil)  
186 of *Ae. aegypti* ABC transporter and thus demonstrates a possible role for these proteins to  
187 impede the transport of the anticholinesterases to their target site (AChE) within the mosquito  
188 central nervous system. Current research activities are focused on the molecular characterization  
189 of mosquito ABC transporter(s) as a first step towards the identification of ABC transporter  
190 interactions and the validation of potential resistance mechanisms against insecticidal  
191 chemistries. Further analysis should be conducted to determine the relationship between selective  
192 ABC transporter expression and their potential for drug transport. The long term goal of this  
193 research study is to provide a better understanding of “chemomodulators” that might be used to  
194 enhance the effectiveness of insecticides that are ABC transporter substrates (e.g., pyrethroids  
195 and carbamates for mosquito control).

196 **Table 1.** Toxicity of tacrine, *bis(7)*-tacrine, and verapamil, alone and in combination, to adult mosquitoes, *Ae. aegypti*.

Compound <sup>a</sup>	No.	LD <sub>50</sub> (µg/mosquito) <sup>b</sup>	95% CI	Slope ± SE
Tacrine	240	30.00 ± 7.07% Mortality	N/A	N/A
Tacrine + Verapamil	240	6.31	5.83 - 6.81	7.54 ± 1.36
<i>Bis(7)</i> -Tacrine	240	27.50 ± 4.79% Mortality	N/A	N/A
<i>Bis(7)</i> -Tacrine + Verapamil	240	1.86	1.45 - 2.26	3.18 ± 0.52
Verapamil	240	10.00 ± 4.08% Mortality	N/A	N/A


197  
 198 <sup>a</sup>Each compound was topically administered as 0.2-µl aliquots to the dorsal thorax of the mosquitoes for 24 h.

199 <sup>b</sup>Tacrine, *bis(7)*-tacrine, and verapamil individual and binary acute toxicity data are presented as LD<sub>50</sub> and their 95% confidence  
 200 intervals (95% CI) in micrograms per mosquito (µg/mosquito), the dose at which 50% of the tested larvae were dead, respectively,  
 201 in a 24-h bioassay. Tacrine, *bis(7)*-tacrine, and verapamil were tested at solubility limits in ethanol and reported as percent  
 202 mortality ± standard error (*n* = 3). Log-probit analysis was used to estimate the endpoint dose for each compound.

203  
 204

205

206



207

208 **Figure 1.** Percent mortality of adult mosquitoes, *Ae. aegypti*, exposed to A) tacrine (THA) at 10 µg/mosquito or B) *bis(7)-tacrine* (7-  
 209 THA) at 5 µg/mosquito alone and in combination with verapamil (VER) at 0.01, 0.1, 1, and 10 µg/mosquito. Vertical bars indicate  
 210 standard errors of the mean ( $n = 4$ ). Different letters on the bars indicate that the means are significantly different among the  
 211 treatments using a one-way analysis of variance and Tukey's multiple comparison test ( $p < 0.05$ ).

212  
213  
214  
215  
  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232

## CHAPTER 4

### ACETYLCHOLINESTERASE AND ABC TRANSPORTER ATPASE ACTIVITY IN MOSQUITOES TREATED WITH TACRINE, *BIS(7)*-TACRINE, AND VERAPAMIL

#### 4.1 Introduction

Insecticide resistance is increasing at significant rate due to re-emergence of mosquito-borne diseases such as dengue, zika virus, and chikungunya, which are transmitted by the *Aedes aegypti* mosquito (Luz *et al.*, 2011; Vontas *et al.*, 2012). The extensive use of insecticides coupled with genetic modifications has decreased susceptible *Ae. aegypti* populations to several insecticides, thereby limiting their use. The lack of effective vaccine and treatments results in a demand for an alternative method to reduce disease transmission. These mosquito species are domesticated and have evolved to breed in assorted environments such as used car tires, old plastic cartons, tree holes, flower vases, and small crevices (Tatem *et al.* 2006; Ferguson *et al.* 2010). Resistance to insecticides can be caused by different mechanisms including reduced insecticide penetration through the cuticle, modification of the insecticide target site, and metabolic resistance through detoxification enzymes such as cytochrome P450s, general esterases and glutathione *S*-transferases (Hemingway and Craig, 2004; Ranson and Hemingway, 2005; Hartsel *et al.* 2012; Mutunga *et al.* 2015). Due to these factors, the understanding of insecticide resistance mechanism is essential for the development of chemical control strategies and development of novel insecticides for the control of disease vectors worldwide.

233 Acetylcholinesterase is a highly effective target-site for two major insecticides: carbamates and  
234 organophosphates. AChE is critical for sustaining life within mammals and insects due to the  
235 regulation of neurotransmitter acetylcholine (ACh) (Weill et al 2002; Mutunga et al. 2015). It  
236 serves to hydrolyze ACh within cholinergic synapses by terminating synaptic transmission in the  
237 central nervous system (Anderson et al. 2009; Mutunga et al. 2013; Wong et al. 2009).  
238 Inhibition of AChE will lead to repeated nerve stimulation, paralysis, and eventual death of the  
239 insect. Although many anticholinesterases inhibitors have high insect toxicities, target-site  
240 insensitivity (G119s mutation) has reduced the efficacy of the AChE targeted insecticides (Wong  
241 et al. 2009). The emergence of carbamate- and organophosphate-resistant mosquito populations  
242 has led to the characterization of AChE target site.

243  
244 A pharmacological approach with experimental compounds using *bis(n)*-tacrine was used to  
245 map the catalytic gorge of acetylcholinesterase in humans and several species of mosquitoes  
246 (Anderson et al. 2009). These *bis(n)*-tacrine are two tacrine dimers connected with 2-12  
247 methylene linkers. A greater maximal potency for *bis(7)*-tacrine was observed in mosquitoes,  
248 indicating a tether length dependency (Anderson et al. 2009). However, due to their lack of  
249 toxicity to live mosquitoes, Mutunga et al. (2013) suggests the lack of toxicity is likely due to the  
250 blood-brain barrier preventing penetration of dimeric tacrine into the CNS. Results discussed in  
251 Mutunga et al. (2013) reported greater firing frequency in the transected *Drosophila*  
252 *melanogaster* CNS compared to the intact CNS, consistent with the lack of observed toxicity.

253  
254 In all domain of life (bacteria, archae, eukarya), multidrug resistance (MDR) is often related to  
255 the ATP-binding cassette (ABC) transporter protein family, the largest transporter family

256 (Demauw et al 2013). The ability of ABC transporters to effectively limit the penetration of  
257 compounds into select intracellular environment can influence the efficacy of a drug by  
258 restricting its interaction with the target site. Zhang et al (2003) suggest that modification of  
259 these ABC transporters may effectively improve the efficacy of compounds to CNS and target  
260 site. These functional transporters consist of two transmembrane domains and two nucleotide  
261 binding domains that contain the Walker A, Walker B and ABC signature motifs and are  
262 involved in the transport of substrates across membranes via the ATP energy-driven process  
263 (Lage et al.2003; Buss et al. 2002; Poretta et al. 2008). The over-expression of some members of  
264 this protein family, such as P-glycoproteins (P-gp/MDR/ABCB1) has caused multidrug  
265 resistance due to a decrease drug concentration to the target site (Lespine et al. 2012). However,  
266 very limited information is reported regarding ABC transporter interaction in mosquitoes; the  
267 majority is in humans, nematodes, or bacteria.

268

269 ABC transporters have been found in several insect species such as mosquitoes, tobacco  
270 hornworm, and fruit flies to provide a defense against insecticides (Buss *et al.*, 2002; Bariami et  
271 al. 2012; Broehan et al. 2013; Figueira et al. 2014; Porretta *et al.*, 2008). The interaction of ABC  
272 transporters inhibitors such as verapamil or ivermectin with insecticides have been shown to have  
273 an increased in insecticide toxicity in resistant insect strains with over-expressed ABC  
274 transporters (Buss *et al.*, 2002; Figueria et al. 2014; Porretta *et al.*, 2008). Classic MDR  
275 modulators, including verapamil, quinidine, ivermectin, and cyclosporin A, are known inhibitors  
276 of the MDR phenotype. These ABC transporters inhibitors involve blocking drug efflux as a  
277 result of competition between modulators and transport substrates including the basal ATPase  
278 activity of ABC transporters; therefore, they are widely used to understand the interactions of

279 compounds and other inhibitors within these transporters (Figueira et al. 2014). Demauw et al.  
280 (2013) report that these inhibitors bind to ABC transporters and inhibits its transport function.  
281 Thus, a better understanding of ABC transporters interaction with anticholinesterases is of  
282 critical importance for control of mosquito borne diseases.

283

284 This study examined the effects of tacrine, *bis(7)*-tacrine, and verapamil on the  
285 acetylcholinesterase and ABC transporter ATPase activity of the yellow fever mosquito, *Ae.*  
286 *aegypti*. Herein, I report the: 1) inhibition of acetylcholinesterase activity in mosquitoes treated  
287 tacrine and *bis(7)*-tacrine alone and in combination with verapamil and 2) the stimulatory and  
288 inhibitory effects of tacrine, *bis(7)*-tacrine, and verapamil on the ABC transporter ATPase  
289 activity of mosquitoes.

290

## 291 **4.2 Materials and Methods**

### 292 *4.2.1 Chemicals*

293 *Bis(7)*-tacrine, ethanol (EtOH), dimethyl sulfoxide (DMSO), magnesium chloride (MgCl<sub>2</sub>) and  
294 tacrine- 9-Amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate ACROS organics (New  
295 Jersey) were purchased from Fisher Scientific (Pittsburg, PA). Acetylthiocholine iodide (ATCh),  
296 adenosine 5'triphosphate disodium salt (ATP-Na), 5,5'-dithio-bis (2-nitrobenzoic acid) (DTNB),  
297 Ethylene glycol-bis(2-aminoethylether)-N,N,N'N'-tetraacetic acid(EGTA), n-phenylthiourea,  
298 protease inhibitor cocktail, potassium nitrate (KNO<sub>3</sub>), phenylmethylsulfonyl fluoride (PMSF),  
299 sodium azide, sodium dodecyl sulphate (SDS), thapsigargin, trizma base (Tris hydrochloride,  
300 Tris-HCl), and Triton X-100 were purchased from Sigma-Aldrich (St. Louis, MO). Ouabain was  
301 purchased from Chem Service (West Chester, PA). Verapamil was purchased from INDOFINE

302 Chemical Company, Inc. (Hillsborough, NJ). Cyclosporin A, dexamethasone, erythromycin,  
303 ketoconazole, nifedipine, paclitaxel, quinidine, vinblastine were purchase from Sigma-Aldrich  
304 (St. Louis, MO).

305

#### 306 *4.2.2 In Vivo Inhibition of Acetylcholinesterase Activity*

307 A study of acetylcholinesterase (AChE) activity in 3-5 d old adults female mosquitoes treated  
308 with tacrine, *bis(-7)*-tacrine, and verapamil was conducted according to the procedures described  
309 by Anderson et al. (2009) with slight modifications. Adult mosquitoes were exposed to tacrine  
310 (10 µg/mosquito) or *bis(-7)*-tacrine (5 µg/mosquito) at the solubility limit individually and in  
311 combination with a fixed dose of verapamil (20 µg/mosquito). After twenty four hours,  
312 mosquitoes were dissected into head, thorax + abdomen, and whole body (head + thorax +  
313 abdomen) dissections. Each sample was homogenized in ice-cold 0.1 M sodium phosphate (pH  
314 7.8) containing 0.3% Triton X-100 (v/v) at the rate of one hundredadult per 100 µl sodium  
315 phosphate. The individual homogenates were centrifuged at 10,000 x g for 10 min at 4 °C and  
316 the supernatant was used as the enzyme source for measuring AChE activity. The residual  
317 AChE activity in the supernatant was measured using a SpectraMax M2 multimode microplate  
318 reader (Molecular Devices, Sunnyvale, CA) at 405 nm immediately after the addition of  
319 acetylthiocholine iodide (ATChI) and 5,5'-dithio-bis (2-nitrobenzoic acid) (DTNB). The final  
320 concentrations of ATChI and DTNB were 0.4 mM and 0.3 mM, respectively.

#### 321 *4.2.3 In Vitro Activity of ATPase Synthases*

322 The ABC transporter ATP synthase (ATPase) activity of 3-5 d old adults female mosquitoes  
323 treated with tacrine, *bis-7*-tacrine, and verapamil at 0.5 mM was examined using similar

324 procedures described by Figueria et al. (2013) with slight modifications. Adult mosquitoes were  
325 homogenized in ice-cold buffer containing 70% solution A (3 mM ATP-Na, 4 mM MgCl<sub>2</sub>, 1 mM  
326 EGTA, 100 mM Tris-HCL (pH 7.5), 0.5 mM ouabain, 0.01 mM thapsigargin, 1 mM sodium  
327 azide, and 50 mM KNO<sub>3</sub>) and 30% solution B (protease inhibitor cocktail, 3.3 mM PMSF, 4.8  
328 mM EGTA, and 1 mM phenyl thiourea) at the rate of one adult per 1 µl buffer. The individual  
329 homogenates were centrifuged at 10,000 x g for 10 min at 4 °C and the supernatant was used as  
330 the enzyme source for measuring ATPase activity. The supernatants were incubated for 1 h at 37  
331 °C with one concentrations of tacrine, *bis-7-tacrine*, and verapamil prepared in 1% DMSO. The  
332 reaction was stopped with the addition of 250 µl of ice-cold 1% SDS. The residual ATPase  
333 activity in the supernatant was measured using a SpectraMax M2 multimode microplate reader  
334 (Molecular Devices) at 390 nm. In order to measure ATPase activity using a human ABC  
335 transporter, the P-gp-Glo™ Assay System was used to detect changes in luminescence in a  
336 human cell line with select compounds. Cyclosporin A, dexamethasone, erythromycin,  
337 ketoconazole, nifedipine, paclitaxel, quinidine, vinblastine were diluted into a P-gp-Glo™ assay  
338 buffer to a final concentration of 0.5 mM. The ATPase activity was measured using a Promega  
339 GloMax 96 Microplate Luminometer.

340

#### 341 ***4.2.4 Measurement of Total Protein Content***

342 **The total protein content in each sample preparation was determined using a**  
343 **bicinchoninic acid assay as described by Smith et al. (1985) with bovine serum**  
344 **albumin (Sigma Aldrich) as a standard. Mosquitoes were collected and**  
345 **homogenized in ice-cold 0.1 M sodium phosphate buffer (pH 7.8) containing 0.3%**

346 **Triton X-100 (Sigma Aldrich, St. Louis, MO). The individual homogenates were**  
347 **centrifuged at 10,000 x g for 10 min at 4 °C and the supernatant was used as the**  
348 **protein source for measuring protein content. Mosquito homogenates were**  
349 **incubated with a bicinchoninic acid (BCA) (Sigma Aldrich) plus 4% cupric sulfate**  
350 **solution at 37°C for 30 min, after which time protein measurements were performed**  
351 **on a multimode microplate reader at 560 nm.**

#### 352 *4.2.5 Statistical Analysis*

353 The change in relative luminescence units (RLU) was calculated by subtracting the RLU of the  
354 test compound from the RLU of the untreated samples ( $\text{Na}_3\text{VO}_4$ ) to reflect change in ATPase  
355 activity. A one-way analysis of variance in combination with a Tukey's multiple comparison  
356 test was used on the acetylcholinesterase and Dunnett's multiple comparison test was used on  
357 ABC transporter ATPase activity to compare the effects of tacrine, *bis(7)*-tacrine, and verapamil  
358 of the mosquitoes (GraphPad, La Jolla, CA).

359

### 360 **4.3 Results**

#### 361 *4.3.1 In vivo Inhibition of Acetylcholinesterase Activity*

362 The residual activity of AChE in the head, thorax + abdomen, and head + thorax + abdomen of  
363 adult mosquitoes treated with tacrine (5  $\mu\text{g}/\text{mosquito}$ ) and *bis(7)*-tacrine (5  $\mu\text{g}/\text{mosquito}$ ) alone  
364 and in combination with verapamil (20  $\mu\text{g}/\text{mosquito}$ ) is shown in Figure 2. The AChE activity  
365 in mosquito heads treated with a combination of tacrine and verapamil was significantly reduced  
366 by 44.7% compared to the tacrine-only treatment (Fig. 2). However, there was no significant  
367 differences in AChE activity between the thorax + abdomen or head + thorax + abdomen of

368 mosquitoes treated with tacrine alone or in combination with verapamil. Similarly, the AChE  
369 activity in mosquito head treated with a combination of *bis(7)*-tacrine and verapamil was  
370 significantly reduced by 70.6% compared to the *bis(7)*-tacrine-only treatment (Fig. 2). Again,  
371 there was no significant differences in AChE activity between the thorax + abdomen or head +  
372 thorax + abdomen of mosquitoes treated with *bis(7)*-tacrine alone or in combination with  
373 verapamil.

374

#### 375 *4.3.2 In vitro Analysis of ABC Transporter ATPase Activity*

376 The ABC transporter ATPase activity in adult mosquitoes treated with verapamil (20  
377  $\mu\text{g}/\text{mosquito}$ ), tacrine (5  $\mu\text{g}/\text{mosquito}$ ), and *bis(7)*-tacrine (5  $\mu\text{g}/\text{mosquito}$ ) is shown in Figure 3.  
378 The ATPase activity of mosquitoes treated with verapamil, tacrine, and *bis(7)*-tacrine was  
379 significantly increased by 1.9-, 8.1-, and 8.1-fold, respectively, compared to the basal ATPase  
380 activity of the untreated mosquitoes (Fig. 3). The ATPase activity of a human ABC transporter  
381 expressed in a cell line treated with class I (i.e., the concentration-dependent activation of  
382 ATPase activity observed at low concentrations and inhibition at higher concentrations) and II  
383 ABC transporter (i.e., the concentration-dependent activation of ATPase activity) substrates is  
384 shown in Figure 3. The ATPase activity of the human ABC transporter treated with the class I  
385 substrate ketoconazole was significantly increased by 2.1-fold whereas cyclosporin A  
386 significantly decreased ATPase activity by 2.9-fold compared to the basal ATPase activity (Fig.  
387 3). The class II substrates erythromycin and nifedipine as well as verapamil significantly  
388 decrease the ATPase activity of the human ABC transporter by 2.4-, 2.3-, and 1.3-fold,  
389 respectively, compared to the basal ATPase activity (Fig. 3). Both tacrine and *bis(7)*-tacrine

390 significantly increase the ATPase activity of the human ABC transporter by 1.1- and 1.3-fold,  
391 respectively, compared to the basal ATPase activity (Fig. 3).

392


#### 393 4.4 Discussion

394 This data gathered in this study suggests that the altered toxicity of tacrine and *bis(7)*-tacrine by  
395 verapamil might be associated with the ABC transporter interference of these anticholinesterases  
396 to their intended target site. The AChE activity in *Ae. aegypti* whole- and thorax and abdomen-  
397 body dissections was not significantly lower for tacrine and *bis(7)*-tacrine with verapamil than  
398 tacrine or *bis(7)*-tacrine only treatments. This result could be due to the chemical release during  
399 preparations of the homogenate. Tacrine and *bis(7)*-tacrine reduce AChE activity in the mosquito  
400 heads by *ca.* 13% and 3%, respectively, compared to control treatments; however, the addition of  
401 verapamil significantly increases the anticholinesterase activity of tacrine and *bis(7)*-tacrine by  
402 *ca.* 45% and 71% respectively, compared to tacrine and *bis(7)*-tacrine-only treatments (Fig. 2).  
403 Therefore, the enhanced inhibitions of AChE by the acetylcholinesterase inhibitors may be the  
404 result of verapamil's effect on modulating ABC transporter activities. This indicates that poor  
405 blood brain barrier penetration could be due to a possible resistance mechanism by mosquito  
406 ABC transporter to transport out substrates and non-substrates.

407

408 This current study shows that tacrine and *bis(7)*-tacrine increase ATPase activity in *Aedes*  
409 *aegypti* at lower concentrations, compared to that of verapamil (Fig. 3). A previous study has  
410 demonstrated that suitable substrates such as verapamil are capable of facilitating reduced  
411 ATPase activity across the ABC transporters through blocking of active ATP sites (Liu et. al  
412 2003). The differential increase in ATPase activity suggests that tacrine and *bis(7)*-tacrine are


413 more suitable substrates for ABC transporter compared to verapamil, consistent with results  
414 found in previous studies (Bariami et al. 2012; Broehan et al. 2013; Figueira et al. 2013, ).Thus  
415 provide putative evidence that ABC transporters are a pharmacological obstacle to the delivery  
416 of these anticholinesterases to their intended target site. This suggest that ATP-binding cassette  
417 transporter positioned within the blood brain barrier could be involved in the BBB penetration  
418 issue of target site delivery of tacrines to the central nervous system. These data are in alignment  
419 with our previous studies that have confirmed the blood-brain barrier of *Drosophila*  
420 *melanogaster* to be a limiting factor in tacrine anticholinesterase toxicity (Mutunga et al. 2012).



431

432 **Figure 2.** Residual acetylcholinesterase (AChE) activity of dissected adult mosquitoes, *Ae. aegypti*, exposed to A) tacrine or B) *bis(7)-*  
 433 tacrine (AChE inhibitors) alone or in combination with verapamil (ABC transporter inhibitor). Tacrine (THA) or *bis(7)-*  
 434 tacrine (7-THA) was topically administered at 10  $\mu$ g or 5  $\mu$ g, respectively, alone or in combination with verapamil (VER) at 20  $\mu$ g for 24 h.  
 435 Vertical bars indicate standard errors of the mean ( $n = 4$ ). Asterisks on the bars indicate that the means are significantly different  
 436 among the treatments for each dissection using a one-way analysis of variance and Tukey's multiple comparison test ( $p < 0.05$ ). CK =  
 437 control, H = head dissection, TH + AB = thorax and abdomen dissection, H + TH + AB = whole body.

438  
439  
440  
441  
442  
443  
444  
445  
446  
447



448 **Figure 3.** Luminescence measurement of adult mosquitoes, *Ae. aegypti*, and human ABC transporter  
449 substrates. A) Mosquitoes were treated with 0.5 $\mu$ M verapamil, tacrine, or *bis(7)*-tacrine. B) Human ABC transporter cell line was  
450 treated with verapamil, tacrine, or *bis(7)*-tacrine as well as class I (ketoconazole, paclitaxel, vinblastine, cyclosporin A) and II  
451 (erythromycin, nifedipine, quinidine, dexamethasone, verapamil) ABC transporter substrates at 0.5 mM concentrations. Vertical bars  
452 indicate standard errors of the mean ( $n = 4$ ). Asterisks on the bars indicate that the means are significantly different among the basal  
453 treatments (control = Basal ATPase, untreated) using Dunnett's multiple comparison test ( $p < 0.05$ ).

454 **CHAPTER 5**

455 **SUMMARY**

456

457 The specific aim of this study was to evaluate the ABC transporter interaction to impede the  
458 ability of tacrine-based compounds to reach the target site in the yellow fever mosquito, *Aedes*  
459 *aegypti*. The anticholinesterase inhibitors tacrine and *bis(7)*-tacrine and verapamil were used in  
460 this study. The mosquitoes were first exposed to tacrine alone and in combination with  
461 verapamil to examine the ABC transporters inhibitor (verapamil) interaction to the acute  
462 toxicities. Second, the acetylcholinesterase and ATPase activities were used to examine the  
463 metabolic detoxification and substrate favorability in the adult mosquito.

464

465 Acetylcholinesterase are enzymes that are able to hydrolyze acetylcholine in the central nervous  
466 system resulting in the buildup of ACh in the nerve synapse and resulting in causing death  
467 (Anderson et al. 2009). Tacrine and *bis(7)*-tacrine are experimental AChE inhibitors and  
468 verapamil is a known ABC transporter inhibitor. The literature suggests that metabolic and  
469 target site resistance limits anticholinesterases their ability to reach their intended target site  
470 resulting in a decrease in toxicity (Mutunga et al. 2013).

471

472 The goal of this study was to examine the acute toxicities of tacrine and *bis(7)*-tacrine alone and  
473 in combination of verapamil to *Ae. aegypti* adult as well as acetylcholinesterase and ATPase  
474 activities of the adult exposure to verapamil. The data gathered in this study provides evidence  
475 for insecticide transport substrates (tacrine and *bis(7)*-tacrine) and inhibitory ligands (verapamil)  
476 in *Ae. aegypti* adult may alter the toxic action of anticholinesterases to their target site within the

477 mosquito central nervous system. The overall hypothesis behind this proposed research is that  
478 ABC transporters impede the ability of tacrine-based compounds to inhibit AChE and, thus,  
479 reduce the toxicity of these anticholinesterases to *Ae. aegypti* adult.

480

481 This study demonstrates that adult treated tacrine, bis(7)-tacrine, and verapamil (ABC transporter  
482 inhibitor) were not acutely toxic to mosquito. When combined with compounds such as  
483 verapamil, tacrine and bis(7)-tacrine toxicity increased in *Ae. aegypti* adult. An increased of  
484 mosquitoes to toxicity when exposed to verapamil, along with an increase in mortality as  
485 verapamil dose increases suggest that verapamil inhibits ABC transporters when applied in  
486 combination with tacrine and bis(7)-tacrine to bypass the BBB in adult mosquito and, in turn,  
487 reach the target site. Thus, these data are in alignment with our previous studies that have  
488 confirmed the blood-brain barrier of *Drosophila melanogaster* to be a limiting factor in tacrine  
489 anticholinesterase toxicity (Mutunga et al. 2012).

490

491 The second objective of this study was to examine the acetylcholinesterase and ATPase activities  
492 in order to understand the metabolic detoxification and substrate favorability in the adult  
493 mosquito. I observed a decrease in residual anticholinesterase activity within mosquitoes  
494 exposed to tacrine or bis(7)-tacrine in combination with verapamil. In addition, our results  
495 indicated that tacrine and bis(7)-tacrine increase ATPase activity in *Ae. aegypti* at lower  
496 concentrations compared to that of verapamil. These results suggest that ABC transporters play  
497 a role in the transport of insecticides to the intended target site and a blood-brain barrier is a  
498 limiting factor in tacrine anticholinesterase toxicity, aligning with results found by Mutunga et  
499 al. (2013). However, additional experiments focused on the molecular characterization of

500 mosquito ABC transporters in *Ae. aegypti* to understand ABC transporter interactions and  
501 resistance mechanism against insecticides. These results also suggest that tacrine and bis(7)-  
502 tacrine are more suitable substrates for ABC transporters compared to verapamil and, thus,  
503 provide evidence that ABC transporters is a pharmacological obstacle to the delivery of these  
504 anticholinesterases to their intended target site and plays a role in insecticide resistance similar to  
505 the one observed in the MDR phenotype. These results are similar to those found in other  
506 studies (Demauw et al. 2014; Lage et al. 2012).

507

## References

- 508  
509
- 510 Adelman, Z.N., Kilcullen, K.N., Koganemaru, R., Anderson, M.A, Anderson, T.D., Miller, D.M.  
511 2011. Deep sequencing of pyrethroid-resistant bed bugs reveals multiple mechanism of  
512 resistance within a single population. *PLoS One* 6: 10: e26228.
- 513 Ahoua Alou, L. P., A. A. Koffi, M. A. Adja, E. Tia, P. K. Kouassi, M. Kone, and F. Chandre.  
514 2010. Distribution of ace-1R and resistance to carbamates and organophosphates in  
515 *Anopheles gambiae* s.s. populations from Cote d'Ivoire. *Malar J* 9: 167.
- 516 Ahmad, M., Denholm, I., Bromilow, R.H., 2005. Delayed cuticular penetration and enhanced  
517 metabolism of deltamethrin in pyrethroid-resistant strains of *Helicoverpa armigera* from china  
518 and pakistan. *Pest Manag Sci* 62: 805-810.
- 519 Anderson. T. D., Paulson, S. L., Wong, D. M., Carlier, P. R., Bloomquist, J. R., 2009.  
520 Pharmacological mapping of the acetylcholinesterase active site gorge in mosquitoes with  
521 bis(n)-tacirines. In: *Advanced in Human Vector Control. American Chemical Society*  
522 *Symposium Series*. 1014:143-151
- 523 Bariami, V., Jones, C.M., Poupardin, R., Vontas, J., Ranson, H., 2012. Gene Amplification, ABC  
524 Transporters and Cytochrome P450s: Unraveling the Molecular Basis of Pyrethroid  
525 Resistance in the Dengue Vector, *Aedes aegypti*. *PLoS Negl Trop Dis* 6:6:e1692.
- 526 Bhatt, Samir; Gething, Peter W; Brady, Oliver J; Messina, Jane P; Farlow, Andrew W et al.,  
527 2013. *Nature* vol. 496 (7446): 504-7
- 528 Bloomquist J. (1999). *Insecticides: Chemistries and Characteristics*. Radcliffe's IPM World  
529 Textbook. University of Minnesota, St. Paul, MN.

530 Broehan, G., Kroeger, T., Lorenzen, M., Merzendorfer, H., 2013. Functional analysis of the  
531 ATP-binding cassette (ABC) transporter gene family of *Tribolium castaneum*. *BMC*  
532 *Genomics* 14:6.

533 Buss, D. S., A. R. McCaffery, and A. Callaghan. 2002. Evidence for p-glycoprotein modification  
534 of insecticide toxicity in mosquitoes of the *Culex pipiens* complex. *Med Vet Entomol* 16:  
535 218-22.

536 Carlier, P. R., Anderson, T. D., Wong, D. M., Hsu, D. C., Hartsel, J., Ma, M., Wong, E.,  
537 Choudhury, R., Lam, P.C-H., Totrov, M., Bloomquist, J. R., 2008. Towards a species-  
538 selective acetylcholinesterase inhibitor to control the mosquito vector of malaria, *Anopheles*  
539 *gambiae*. *Chem. Biol. Interact.* 175:368-375

540 Casida, J. E., and Quistad, G. B., 2004. Why insecticides are more toxic to insects than people:  
541 The unique toxicology of insects. *J Pestic. Sci.* 29(2); 81 - 86.

542 Dauchy, S., Dutheli, F., Weaver, R.J., Chassoux, F., Daumas-Duport, C., Couraud, P.O.,  
543 Scherrmann, J.M., De Waziers, I., Decleves, S., 2008. ABC transporters, cytochromes P450  
544 and their main transcription factors: expression at the human blood-brain barrier. *J*  
545 *Neurochem* 107: 1518-28.

546 Dermauw, W., Van Leeuwen, T., 2013. The ABC gene family in arthropods: Comparative  
547 genomics and role in insecticide transport and resistance. *Insect Biochem and Mol Biol.* 45:  
548 89-110.

549 Ellman, G. L., Courtney, K. D., Andres, B., Featherstone, R. M., 1961. A new and rapid  
550 colorimetric determination of acetylcholinesterase activity. *Biochem. Pharmacol.* 7:88-95

551 Enayati, A.A., Ranson. H., Hemingway, J., 2005. Insect glutathione transferases and insecticide  
552 resistance. *Insect Mol. Bio..* 14:3-8.

553 Ferguson, H.M., Dornhaus, Beeche, A., Borgemeister, C., Gottlieb, M. Mulla, M.S., Gimnig,  
554 J.E., Fish, D., Killeen, G.F., 2010. Ecology: a prerequisite for malaria elimination and  
555 eradication. *PloS Med.* 7:8:e1000303.

556 Figueira-Mansur, J., Ferreria-Pereira, A., Mansur, J. F., Franco, T.A., Alvarenga, E.L., Sorgine,  
557 M.F., Neves, B.C., Melo, A.A, Leal, W.S., Masuda, H., Moreira, M.F., 2013. Silencing of P-  
558 glycoprotein increase mortality in temephos-treated *Aedes aegypti* larvae. *Insect Mol. Biol.*  
559 22: 648-658.

560 Gubler, D. J., 1998. Dengue and Dengue Hemorrhagic Fever. *Clin. Microbiol. Rev.* 11: 480–496.

561 Gubler, D. J., 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and  
562 economic problem in the 21st century. *Trends. Microbiol.* 10: 100–103.

563 Hartsel, J. A., D. M. Wong, J. M. Mutunga, M. Ma, T. D. Anderson, A. Wysinski, R. Islam, E.  
564 A. Wong, S. L. Paulson, J. Li, P. C. H. Lam, M. M. Totrov, J. R. Bloomquist, and P. R.  
565 Carlier. 2012. Re-engineering aryl methylcarbamates to confer high selectivity for inhibition  
566 of *Anopheles gambiae* versus human acetylcholinesterase. *Bioorganic Medicinal Chemistry*  
567 *Letters* 22: 4593-4598.

568 Hemingway, J., 2000. The molecular basis of two contrasting metabolic mechanisms of  
569 insecticide resistance. *Insect Biochemistry and Molecular Biology*, 30: 1009–15.

570 Hemingway, J., and H. Ranson. 2000. Insecticide resistance in insect vectors of human disease.  
571 *Annu Rev Entomol* 45: 371-91.

572 Hemingway, J., Field, L., Vontas, J., 2002. An overview of insecticide resistance. *Science*, 298:  
573 96–97.

574 Hemingway, J., and A. Craig. 2004. Parasitology. New ways to control malaria. *Science* 303:  
575 1984-5.

576 Hemingway, J., Beaty, B. J., Rowland, M., Scott, T. W., Sharp, B. L., 2006. The Innovative  
577 Vector Control Consortium: improved control of mosquito-borne diseases. *Trends Parasitol.*  
578 22:308–312.

579 Jin-Clark, Y., Anderson, T. D., K. Y. Zhu., 2008. Effect of alachlor and metolachlor on the  
580 toxicity of chlorpyrifos and major detoxification enzymes in the aquatic midge, *Chironomus*  
581 *tentans* (Diptera: Chironomidae). *Arch. Environ. Contam. Toxicol.* 54:645-652

582 Labbe, R., Caveney, S., Donly, C., 2010. Expression of multidrug resistance protein is localized  
583 principally to the Malpighian tubules in larvae of the cabbage looper moth, *Trichoplusia ni*. *J*  
584 *Exp Biol.* 214: 937-944.

585 Lage, H., 2003. ABC-transporters: implications on drug resistance from microorganisms to  
586 human cancers. *Antimicrobial Agents.* 22: 188-199.

587 Leader, J.P., O'Donnell, M.J., 2005. Transepithelial transport of fluorescent p-glycoprotein and  
588 MRP2 substrates by insect Malpighian tubules: confocal microscopic analysis of secreted  
589 fluid droplets. *J Exp Biol.* 208:4363-4376.

590 Lespine, A., Menezz, C. Bourguinat, C., Prichard, R.K., 2012. P-glycoproteins and other  
591 multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for  
592 reversing transport-dependent anthelmintic resistance. *Int. J Para: Drugs and Drug*  
593 *Resistance.* 2: 58-75.

594 Lopez-Marques, R., Poulsen, L.R., Bailly, A., Geisler, M., Pomorski, T.G., Palmgren, M.G.,  
595 2014. Structure and mechanism of ATP-dependent phospholipid transporters. *Biochem et*  
596 *Biophys Acta.* 4:04-08.

597 Luz, P.M., Lima-Camara, T.N., Bruno, R.V., Castro, M.G., Sorgine, M.H., Lourenco-de-  
598 Oliveira, R., Peixoto, A.A., 2011. Potential impacts of a presumed increase in biting activity

599 of dengue-virus-infected *Aedes aegypti* (diptera: culicidae) females on virus transmission  
600 dynamics. *Mem Inst Oswaldo Cruz*. 106: 755-758.

601 Mayer, F., Mayer, N., Chinn, L., Pinsonneault, R. L., Kroetz, D., Bainton, R. J., 2009.  
602 Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in  
603 *Drosophila*. *J Neurosci* 29: 3538-50.

604 McCarroll, L., Paton, M.G., Karunaratne, S.H., Jayasuryia, H.T., Kalpage, K.S., Hemingway, K.,  
605 2000. Insecticide and mosquito-brone disease. *Nature* 407: 961-962.

606 Mutunga, J. M, Anderson, T. D., Wong, D. M., Boina, D. R., Carlier, P. R., and Bloomquist, J.  
607 R. 2013. Neurotoxicology of bis(n)-tacrine on *Blattella germanica* and *Drosophila*  
608 *melanogaster* acetylcholinesterase. *Arch Insect Biochem Physiol* 83:180-194

609 Mutunga, J. M, Anderson, T. D., Craft D. T., Gross A.D., Swale D.R., Tong F., Wong, D. M.,  
610 Carlier, P. R., and Bloomquist, J. R. 2015. Carbamate and pyrethroid resistance in akron  
611 strain of *Anopheles gambiae*. *Pesticide Biochem Physiol* 21:116-124

612 Okumu, F. O., and S. J. Moore. 2011. Combining indoor residual spraying and insecticide-  
613 treated nets for malaria control in Africa: a review of possible outcomes and an outline of  
614 suggestions for the future. *Malar J* 10: 208.

615 Prapanthadara, L.,Kootathep, S., Promlet, N., Hemingway, J., Ketterman A.J., 1996.  
616 Purification and characterization of a major glutathione S-transferase from the mosquito  
617 *Anopheles dirus* (species B). *Insect Biochem. Mol. Biol.* 26:277-285.

618 Porretta, D., M. Gargani, R. Bellini, A. Medici, F. Punelli, and S. Urbanelli. 2008. Defence  
619 mechanisms against insecticides temephos and diflubenzuron in the mosquito *Aedes caspius*:  
620 the P-glycoprotein efflux pumps. *Med Vet Entomol* 22: 48-54.

621 Pridgeon, J. W., Becnel, J. J., Clark, G. G., Linthicum, K. J., 2009. A high-throughput screening  
622 method to identify potential pesticides for mosquito control. *J. Med. Entomol.* 46(2):335-341

623 Ranson H, Jensen B, Vulule J, Wang X, Hemingway J, and Collins F. (2000). Identification of a  
624 point mutation in the voltage gated sodium channel gene of Kenyan *Anopheles gambiae*  
625 associated with resistance to DDT and pyrethroids. *Insect Molecular Biology.* 9:491-497

626 Ranson H, Rossiter L, Ortelli F, Jensen B, Wang X, Roth C, Collins F, and Hemingway J.  
627 (2001). Identification of a novel class of insect glutathione S-Transferases involved in  
628 resistance to DDT in the malaria vector *Anopheles gambiae*. *Journal of Biochemistry.* 359  
629 (pt.2):295-304.

630 Roth, C. W., I. Holm, M. Graille, P. Dehoux, A. Rzhetsky, P. Wincker, J. Weissenbach, and P.  
631 T. Brey. 2003. Identification of the *Anopheles gambiae* ATP-binding cassette transporter  
632 superfamily genes. *Mol Cells* 15: 150-8.

633 Safa, A. R., 2004 Identification and Characterization of the binding sites of P-glycoprotein for  
634 multidrug resistance-related drugs and modulators. *Current Medicinal Chemistry-Anti*  
635 *Cancer Agents.* 4:1-17

636 Scott, J.G., Yoshimizu, M.H., Kasai, S. 2015. Pyrethroid Resistance in *Culex Pipens* mosquitoes.  
637 *Pestic Biochem Physiol* 120: 68-76.

638 Serazin AC, Dana AN, Hillenmeyer ME, Lobo NF, Coulibaly MB. Comparative analysis of the  
639 global transcriptome of *Anopheles funestus* from Mali, West Africa. *PLoS One.*  
640 2009;4:e7976.

641 Simmons, J., D'Souza, O., Rheault, M. Donly, C., 2013. Multidrug resistance protein gene  
642 expression in *Trichoplusia ni* caterpillars. *Insect Mol. Biol.* 22: 62-71.

643 Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D.,  
644 Fujimoto, E. K., Goeke, N. M., Olson, B. J., Klenk, D. C., 1985. Measurement of protein  
645 using bicinchoninic acid. *Anal. Biochem.* 150, 76-85

646 Tak, J.H., Isman, M.B., 2015. Enhanced cuticular penetration as the mechanism for synergy of  
647 insecticidal constituents of rosemary essential oil in *Trichoplusia ni*. *Sci Rep.* 5: 12690.

648 Taub, M.E., Podila, L., Ely, D. Almeida, I., 2005. Functional assessment of multiple p-  
649 glycoprotein (-gp) probe substrates: influence of cell line and modulator concentration on p-  
650 gp activity. *Drug Metabolism and Disposition.* 33: 1679-1687.

651 Vinson, S. B. and Law, P. K., 1971. Cuticular composition and DDT resistance in the tobacco  
652 budworm. *J. Econ. Entomol.* 64: 1387-1390.

653 Tatem A.J., Rogers D.J., Hay S.I., 2006. Global transport networks and infectious disease  
654 spread. *Adv. Parasitol.* 62: 293- 343.

655 Vinson, S. B. and Law, P. K., 1971. Cuticular composition and DDT resistance in the tobacco  
656 budworm. *J. Econ. Entomol.* 64: 1387-1390.

657 Vontas, J., Kioulos, E., Pavlidi, N., Morou, E., della Torre, A., and Ranson, H., 2012.  
658 Insecticide resistance in the major dengue vectors *Aedes albopictus* and *Aedes aegypti*.  
659 *Pestic. Biochem. Physiol.* 104:126-131

660 Weill, M., Fort, P., Berthomieu, A., Dubois, M. P., Pasteur, N., & Raymond, M., 2002. A novel  
661 acetylcholinesterase gene in mosquitoes codes for the insecticide target and is non-  
662 homologous to the ace gene in *Drosophila*. *Proc. Biolog. Sci. / The Royal Society*,  
663 269(1504):2007–16.

664 Wong, D. M., Li, J., Chen, Q., Han, Q., Mutunga, J. M., Wysinski, A., Anderson, T. D., Ding,  
665 H., Carpenetti, T. L., Astha, Islam, R., Paulson, S. A., Lam, P. C. H., Totrov, M. M.,

666 Bloomquist, J. R., Carlier, P. R., 2012. Select small core structure carbamates exhibit high  
667 contact toxicity to “carbamate-resistant” strain malaria mosquitoes, *Anopheles gambiae*  
668 (Akron). *PLoS ONE*. 7(10):e46712

669 Wood, O., S. Hanrahan, M. Coetzee, L. Koekemoer, and B. Brooke. 2010. Cuticle thickening  
670 associated with pyrethroid resistance in the major malaria vector *Anopheles funestus*. *Parasit*  
671 *Vectors* 3: 67.

672 World Health Organization. 2006. Guidelines for testing mosquito adulticides for indoor residual  
673 spraying and treatment of mosquito nets. Document  
674 WHO/CDS/NTD/WHOPES/GCDPP/2006.3. Geneva

675 World Health Organization. 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and  
676 Control. Document WHO/HTM/NTD/DEN/2009.1. Geneva

677 Yu, S. J., 1996. Insect glutathione S-transferases. *Zool. Stud.* 35(1): 9-19.

678 Yu, S. J., 2008. The Toxicology and Biochemistry of Insecticides. Boca Raton, FL: CRC Press,  
679 pp. 235-240.

680 Zhang, Y., Bachmeier, C. Miller, D.W., 2003. In vitro and in vivo models for assessing drug  
681 efflux transporter activity. *Adv Drug Delivery Reviews*. 55: 31-51.